Safety and Efficacy of Pulmonary Rehabilitation for Long COVID Patients Experiencing Long-Lasting Symptoms

Author:

Moine Espérance1ORCID,Molinier Virginie1,Castanyer Adriana2,Calvat Amandine3,Coste Guillaume2,Vernet Antonin2,Faugé Audrey3,Magrina Perrine3,Aliaga-Parera Joan Lluis2,Oliver Nicolas13,Alexandre François1,Heraud Nelly1

Affiliation:

1. Direction de la Recherche Clinique et de l’Innovation en Santé, Clariane, 34700 Lodève, France

2. Clinique du Souffle La Solane, Inicea, 66340 Osséja, France

3. Clinique du Souffle La Vallonie, Inicea, 34700 Lodève, France

Abstract

Due to the high prevalence and persistence of long COVID, it is important to evaluate the safety and efficacy of pulmonary rehabilitation (PR) for patients who experience long-lasting symptoms more than six months after initial COVID-19 onset. Enrolled patients were admitted for a four-week in-patient-PR due to long COVID symptoms (n = 47). The safety of PR was confirmed by the absence of adverse events. Symptom-related outcomes were evaluated pre- and post-PR with significant score changes for: 6 min walking distance (61 [28 to 103] m), quality of life (mental Short Form-12: 10 [6 to 13], and physical: 9 [6 to 12]), Montreal Cognitive Assessment (1 [0 to 3]), fatigue (MFI-20: −19 [−28 to −8]), dyspnea (DYSPNEA-12: −7 [−9 to −2] and mMRC; −1 [−1 to 0]), Nijmegen questionnaire (−8 [−11 to −5]), anxiety and depression (HADS:−4 [−5 to −2] and −2 [−4 to −1], respectively) and posttraumatic stress disorder checklist scale (−8 [−12 to −4]). At the individual level, the percentage of symptomatic patients for each outcome decreased, with a high response rate, and the number of persistent symptoms per patient was reduced from six at PR initiation to three at the end of the program. Our results show that in-PR is safe and efficient at decreasing long-lasting symptoms experienced by long COVID patients at more than six months after initial disease onset.

Publisher

MDPI AG

Reference87 articles.

1. A clinical case definition of post-COVID-19 condition by a Delphi consensus;Soriano;Lancet Infect. Dis.,2022

2. Santé Publique France (2022). Résultats de L’enquête Affection Post-COVID, Santé Publique France. 22 Mars–8 Avril 2022.

3. Office for National Statistics (2023). Prevalence of Ongoing Symptoms Following Coronavirus (COVID-19) Infection in the UK 5 January 2023, Statistical Bulletin.

4. National Center for Health Statistics, and U.S. Census Bureau (2023, January 30). Long COVID. Household Pulse Survey, 2022–2023, Available online: https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm.

5. Post-COVID-19 syndrome: Epidemiology, diagnostic criteria and pathogenic mechanisms involved;Rev. Neurol.,2021

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3